Abstract Details

Title Fatal leukoencephalopathy in a patient with multiple sclerosis following treatment with ocrelizumab

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 353

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Robert Kadish, MD PRESENTER	Dr. Kadish has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. The institution of Dr. Kadish has received research support from Alexion Pharmaceuticals.
David A. Robertson, MD (University of Louisville)	Dr. Robertson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Michael Sweeney, MD (University of Louisville)	Dr. Sweeney has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genentech. Dr. Sweeney has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.